SMi’s 4th Annual ADC Summit 2015 will be taking place in just over 2 weeks’ time on the 18th – 19th May 2015 in London, UK. The event will include 30+ leading organisations, 4 hours of networking, 1 round table discussion and 1 workshop.
In the run up to the event, Chief Scientific Officer Mahendra Deonarain from Antikor Biopharma Ltd, was asked a few questions about his upcoming presentation at the conference. Mahendra’s knowledge will provide invaluable insight into the fascinating and evolving area of antibody drug conjugates as he speaks on day 1 of the event, highlighting Opti-linked Antibody Fragments as ADCs.
When asked to describe his role and current activities, Mr Deonarain said:
“I’m the CSO and COO for Antikor Biopharma. We recently renamed when we moved from our small labs at Imperial College to our own premises at the Stevenage Bioscience Catalyst and focussed on ADCs rather than phototherapy.
I manage the ADC R&D program as well as our collaborations but spend a lot of time ensuring that we are operating effectively now that we are completely independent. I am part of the management team that strategically plans where our fragment-based ADC program is going.”
On what he thought the strengths of this year’s ADC Summit are, he commented:
“The program is varied giving a great insight into all aspects of ADCs. As important, the venue allows close networking and the establishment of future partnerships.”
Mr Deonarain expressed what he believes the biggest challenges for the industry are:
“I believe that each cancer has unique features that makes generating a ‘one size fits all’ ADC approach very difficult. Each platform will need to be modified to hit the ‘sweet spot’ making development more risky. I think we are going to see some high profile failures that will dent confidence but raise innovation.”
To read the full interview please visit the download centre at www.drugconjugates.com/biopharmadive
This conference will enable attendees to share, confer and debate how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.
Attendees for this year’s ADC Summit 2015 include: Ablynx, ADC Biotechnology, Albany Molecular Research Inc, Antikor Biopharma Ltd., Bicycle Therapeutics Limited, BioPharmaLogic Ltd., Boult Wade Tennant, Clinical Network Services (UK) Ltd, Crescendo Biologics Ltd, Cristal Therapeutics, Endocyte, Inc., GE Healthcare, ImmunoGen, Inc., Imperial College London, Institut de Recherches Internationales Servier, King's College London, NanoTemper Technologies Ltd, NBE-Therapeutics AG, Novasep S A S, Philochem AG, Queens University Belfast, Regeneron Pharmaceuitcals Inc, Roche Glycart AG, Roche Innovation Center Penzberg, SafeBridge Europe, Limited, Spirogen, Sygnature Discovery Limited, Tagworks Pharmaceuticals, University College London, University of Leeds.
In addition to the event, there will be an interactive half-day post-conference workshop taking place on the 20th May 2015 entitled: ADCs: A Journey Through Development, hosted by Dr. Richard Turner, Principle Consultant, Natalie Thomas, Consultant and Simon Bishop, Associate Consultant at BioDesk
For more information or to register visit www.drugconjugates.com/biopharmadive
Alternatively please contact Fateja Begum on +44 (0) 207 827 6184 or e-mail [email protected]
ADC Summit 2015 is sponsored by: Heraeus Precious Metals & Nanotemper technologies Ltd
-------------------------- END --------------------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
